Document:

EX-10.17

 Exhibit 10.17 
 INVESTORS RIGHTS AGREEMENT 
 THIS INVESTORS RIGHTS AGREEMENT (this
“Agreement”) is made and entered into as of January 3, 2006, by and among Evogene Ltd., a private company organized under the laws of the State of Israel (Reg. No.: 512838723), having its registered offices at Gad
Fienshten 13 Rehovot, Israel (the “Company”) and the Company’s shareholders listed in Schedule A attached hereto (the “Shareholders”). 

R E C I T A L S 

WHEREAS the Company and each of the Shareholders listed in items 8-25 and 35-37 of Schedule A hereof are
parties to the 2nd Amended and Restated Registration
Rights Agreement dated January 11, 2004 (the “Former Amended RRA”), and certain of such Shareholders are the holders of Registrable Securities (as such term is defined therein) (the “Former RRA Registrable
Securities”) currently outstanding or issuable upon conversion of Series A Preferred Shares of the Company and/or Ordinary-1 Shares of the Company currently outstanding; and 

WHEREAS Section 2.2 of the Former Amended RRA provides that with the written consent of the Company, Compugen Ltd. and the consent
of the holders of a majority in interest of the Former RRA Registrable Securities currently outstanding or issuable upon conversion of any Series A Preferred Shares of the Company and/or Ordinary-1 Shares of the Company currently outstanding (the
“Required Majority”), the Company may amend the Former Amended RRA; and 
 WHEREAS, certain of the signatories
hereto constitute the Required Majority; and 
 WHEREAS such signatories agree to amend the Former RRA and replace it in its
entirety with this Agreement; and 
 WHEREAS the Company and the Shareholders desire to set forth certain matters regarding
registration rights and information rights, all as more fully set forth herein; and 
 WHEREAS the Company and the required
majority of those of the signatories hereto that are also parties to the Voting Agreement (as defined below) agree to its cancellation; and 
 WHEREAS the Company and the required majority of those of the signatories hereto that are also parties to the First Loan Agreement and the Second Amendment of the First Loan Agreement (both, as defined
below) agree to cancel certain provisions thereof, as further detailed herein; and 
 WHEREAS the Company and the required
majority of those of the signatories hereto that are also parties to the 2005 Convertible Bridge Loan (as defined below) agree to cancel a certain provision thereof, as further detailed herein; 

 NOW, THEREFORE, in consideration of the foregoing recitals, the mutual promises hereinafter
set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
  

	1.	REGISTRATION RIGHTS 

  

	 	1.1.	In this Section 1: 

  

	 	1.1.1.	“Holder” or “Holders” shall mean the Shareholders; 

 

	 	1.1.2.	“Kadima Holder” shall mean any person or entity for which Kadima holds Registrable Securities in trust. 

 

	 	1.1.3.	“register”, “registered”, and “registration” shall refer to a registration effected by preparing and filing a
registration statement or similar document in compliance with the Securities Act or any similar or applicable securities act in a jurisdiction other than the United States, and the declaration or ordering of effectiveness of such registration
statement or document. 

  

	 	1.1.4.	“Registrable Securities” shall mean Ordinary Shares of the Company, currently held, or hereafter acquired, by the Holders, including without limitation
Ordinary Shares issuable upon conversion of the (i) Series B Preferred Shares of the Company currently outstanding or hereafter issuable pursuant to the exercise of certain warrants that have been granted to certain of the Shareholders;
(ii) Series B-1 Preferred Shares hereafter issuable pursuant to the exercise of certain warrants that have been granted to certain of the Shareholders; (iii) Series A Preferred Shares of the Company currently outstanding or hereafter
issuable pursuant to the exercise of certain warrants that have been previously granted to certain of the Shareholders; or (iv) Ordinary-1 Shares of the Company. Registrable Securities if transferred, in accordance with the Articles of
Association in effect at the time of such transfer, will remain Registrable Securities for the purpose of this Agreement. 

  

	 	1.1.5.	“Securities Act” shall mean the United States Securities Act of 1933, as amended and all regulations promulgated thereunder or under any other similar
law. 

  

	 	1.1.6.	“Series B Share Purchase Agreement” shall mean the Share Purchase Agreement made as of the 3rd day of January, 2006, by and between the
Company, Kadima High - Tech Ltd. (acting as trustee for the persons and entities listed in Schedule A attached thereto); Epione BioInvestment I L.P. and Epione BioInvestment II L.P.; and certain additional investors listed
in Schedule B attached thereto. 	 

  

	 	1.2.	Demand Registration 

  

	 	1.2.1.	 At any time upon the Initial Public Offering (IPO) of the Company and thereafter, but not more than two (2) times during the term of this
Agreement (in the aggregate, for all Holders), any Holder or group of Holders of Registrable Securities which hold an aggregate of at least 12.5% (twelve and one half percent) of the Registrable Securities of the Company then issued (the
“Initiating Holders”), may request in writing (a “Demand”) that the Company uses its best efforts to register such Holders’ Registrable Securities, or any part thereof, for trading on any recognized European or
United States securities exchange or quotation system (“Exchange”) in accordance with the provisions of 

  
 - 2 -

	 	
this Section 1.2, provided however that a Demand for registration in the United States or on any European exchange may only be effected after six (6) months from the consummation
of the Company’s initial public offering in the United States or on such European exchange and provided further that the aggregate anticipated offering price of such Registrable Securities equals at least US$4,000,000. A Demand, which
has not culminated in the registration of the requested Registrable Securities, shall not be counted as a Demand for the purposes of this section, unless the reason for such lack of culmination was due to an action of the Initiating Holders.

  

	 	1.2.2.	As soon as practicable after receipt of the Demand, the Company shall promptly give written notice of the proposed registration, qualification or compliance to all
other Holders, and shall file a registration statement covering such shares and shall take all actions under its power and control to include in such registration, qualification or compliance all Registrable Securities held by Holders who explicitly
expressed their wish to participate in such registration within twenty (20) days after receipt of the Company’s notice. Thereupon the Company shall take all reasonable actions under its power and control to effect such registration as
required and as would permit and facilitate the sale and distribution of all such portion of the Holders’ Registrable Securities as are specified in such request together with all such portion of Registrable Securities of any other Holders
joining in such request as aforesaid. 

  

	 	1.3.	Form F-3 Registration 

  

	 	1.3.1.	At any time upon the IPO of the Company and thereafter, if the Company receives from the Initiating Holders a written request that the Company effect any registration
statement on Form F-3 (or any successor form to Form F-3) for the sale of Registrable Securities, the Company shall as soon as practicable after receipt of such request give notice of proposed registration, qualification or compliance to all other
Holders and shall take all actions under its power and control to include in such registration, qualification or compliance all Registrable Securities held by Holders who explicitly expressed, in writing, their wish to participate in such
registration within twenty (20) days after receipt of the Company’s notice. Thereupon the Company shall take all actions under its power and control to effect such registration as required and as would permit and facilitate the sale and
distribution of all such portion of the Holders’ Registrable Securities as are specified in such request together with all such portion of Registrable Securities of any other Holders joining in such request as aforesaid.

  

	 	1.3.2.	The Company shall not be obligated to affect a registration, qualification or compliance pursuant to this Section 1.3 if (a) Form F-3 is not available for
such offering by the Holders, or (b) the aggregate anticipated offering price of such Registrable Securities equals less than US$2,500,000. 

  
 - 3 -

	 	1.4.	Incidental (“Piggy Back”) Registration 

  

	 	1.4.1.	If at any time, upon the IPO of the Company or thereafter, the Company shall determine to register any of its securities, either for its own account or the account of a
security holder or holders, other than registration relating solely to (a) a registration for the employee benefit plans, including stock option and stock purchase plans, (b) a registration relating solely to a Rule 145 of the Securities
Act transaction or (c) an initial public offering by the Company of its securities in which security holders of the Company do not participate as sellers, the Company will promptly give to each Holder written notice thereof and include in such
registration and in any underwriting involved therein, all the Registrable Securities specified in a written request(s) by a Holder made within twenty (20) days after receipt of the Company’s notice. 

 

	 	1.5.	The Company’s Right to Delay. The Company may delay the filing of any registration statement requested pursuant to Sections 1.2, 1.3 and 1.4, to a
date not more than hundred and twenty (120) days following the date of such request if the Company’s Board of Directors makes a determination in good faith that such a delay is necessary; provided, that the Company may not exercise such
right of delay more than once in any twelve month period. 

  

	 	1.6.	Registration Exemptions. Notwithstanding Sections 1.2 and 1.3 above, the Company shall not be obligated to take any action to effect any such
registration, qualification or compliance: 

  

	 	1.6.1.	In any particular jurisdiction in which the Company would be required to execute a general consent to service of process in effecting such registration, qualification
or compliance unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act. 

  

	 	1.6.2.	If the Company has already effected a registration pursuant to Sections 1.2 and/or 1.3 request of the Holder(s) within twelve (12) months prior to the current
requested registration pursuant to Sections 1.2 and or 1.3 above, and such registration has been declared or ordered effective. 

  

	 	1.6.3.	If, in the opinion of counsel satisfactory to the Company and the respective Holders, the sale of the Registrable Securities owned by such Holders, may then be made in
a transaction exempted from the registration and prospectus delivery requirements of the Securities Act and from the comparable requirements of the applicable state securities laws so that any transfer restrictions may be removed upon the
consummation of such sale. Any and/or all of the Kadima Holders then seeking to effect registration and for which Kadima shall at the time still hold Registrable Securities in trust, shall be treated as one block of Holders of Registrable Securities
for the purpose of this exemption. 

  
 - 4 -

	 	1.7.	Underwriting 

  

	 	1.7.1.	If a registration pursuant to Section 1.2, 1.3 or 1.4 is for a registered public offering involving an underwriting on a firm basis, the Company shall so advise
the Holders as part of the notice given pursuant to Sections 1.2, 1.3, or 1.4, as the case may be. In such event, the right of any Holder to registration pursuant to Sections 1.2, 1.3 or 1.4 shall be conditioned upon such Holder’s participation
in the underwriting arrangements as required by the applicable underwriters and this Section 1.7, and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent requested shall be limited to the extent provided
herein. The Company shall (together with all Holders proposing to distribute their securities through such underwriting) enter into an underwriting agreement with the managing underwriter selected for such underwriting by the Company. If any Holder
of Registrable Securities disapproves of the terms of the underwriting, such person may elect to withdraw therefrom by written notice to the Company, the managing underwriter and the participating Holders. 

 

	 	1.7.2.	Notwithstanding any other provision herein, if the managing underwriter advises the Holders in writing that, in such managing underwriter’s good faith professional
judgment, marketing factors require a limitation of the number of shares to be underwritten, then the number of shares of Registrable Securities that may be included in a registration pursuant to Section 1.2, 1.3 or 1.4, shall be reduced and
allocated among the Holders thereof in proportion, as nearly as practicable to the respective amounts of Registrable Securities held by such Holders at the time of filing the registration statement. No Registrable Securities excluded from the
underwriting by reason of the underwriter’s marketing limitation shall be included in such registration. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of
shares allocated to any Holder to the nearest 100 shares. 

  

	 	1.8.	State Qualification. The Company shall use its best efforts to qualify the sale of Registrable Securities to be included in any registration pursuant to
this Section 1 under the Blue Sky or other applicable laws of such jurisdictions as a Holder may reasonably request. 

  

	 	1.9.	Expenses of Registration. All registration expenses incurred in connection with any registration pursuant to this Section 1 (including up to one
counsel for the Holders) shall be borne by the Company. Unless otherwise agreed, all underwriting discounts, selling commissions and stock transfer taxes applicable to the securities registered by the Holders shall be borne by the Holders of such
securities pro rata on the basis of the number of shares so registered. 

  

	 	1.10.	Registration Procedures 

 In the case of each registration, qualification or compliance effected by the Company pursuant to this Section 1, the Company will keep each Holder advised in writing as to the initiation of each
registration, qualification and compliance and as to the completion thereof. At its expense the Company will: 
  

	 	1.10.1.	Prepare and file with the SEC a registration statement with respect to such securities and use its best efforts to cause such registration statement to become and
remain effective until the earlier of (i) three months after the effective date, or (ii) completion of the distribution described in the registration statement; and 

  
 - 5 -

	 	1.10.2.	Furnish to the Holders participating in such registration and to the underwriters of the securities being registered such reasonable number of copies of the
registration statement, preliminary prospectus, final prospectus and such other documents as such underwriters may reasonably request in order to facilitate the public offering of such securities. 

 

	 	1.11.	Indemnification 

  

	 	1.11.1.	The Company will indemnify each Holder, each of its officers and directors and partners, agents of such Holder (including its legal counsel and independent
accountants), and each person controlling such Holder within the meaning of Section 15 of the Securities Act, with respect to which registration, qualification or compliance has been effected pursuant to this Section 1, against all
expenses, claims, losses, damages or liabilities (or actions in respect thereof), including any of the foregoing incurred in settlement of any litigation, commenced or threatened, arising out of or based on any untrue statement (or alleged untrue
statement) of a material fact contained in any registration statement, prospectus, offering circular or other document, or any amendment or supplement thereto, incident to any such registration, qualification or compliance, or based on any omission
(or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading, or any violation by the Company of the
Securities Act or any rule or regulation promulgated under the Securities Act applicable to the Company in connection with any such registration, qualification or compliance, and the Company will reimburse each such Holder, each of its officers and
directors, and each person controlling such Holder for any legal or any other expenses reasonably incurred in connection with the investigating, preparing or defending any such claim, loss, damage, liability or action, provided that the Company will
not be liable in any such case to the extent that any such claim, loss, damage, liability or expense arises out of or is based on any untrue statement or omission or alleged untrue statement or omission, made in reliance upon and in conformity with
written information furnished to the Company by an instrument duly executed by such Holder, controlling person or underwriter and stated to be specifically for use therein. 

 

	 	1.11.2.	 Each Holder will, if Registrable Securities held by such Holder are included in the securities as to which such registration, qualification or
compliance is being effected, indemnify the Company, each of its directors and officers, agents of the Company (including its legal counsel and independent accountants), and each person who controls the Company within the meaning of Section 15
of the Securities Act, and each other such Holder, each of its officers and directors, agents of such Holder (including its legal counsel and independent accountants) 

  
 - 6 -

	 	
and each person controlling such Holder within the meaning of Section 15 of the Securities Act, against all claims, losses, damages and liabilities (or actions in respect hereof) arising out
of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any such registration statement prospectus, offering circular or other document, or any omission (or alleged omission) to state therein a material fact
required to be stated therein or necessary to make the statements therein not misleading, and will reimburse the Company, such other Holders, such directors, officers, persons or control persons for any legal or any other expenses reasonably
incurred in connection with investigating or defending any such claim, loss, damage, liability or action, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission)
is made in such registration statement, prospectus, offering circular or other document in reliance upon and in conformity with written information furnished to the Company by an instrument duly executed by such Holder and stated to be specifically
for use therein. Notwithstanding the foregoing, the liability of each Holder under this subsection 1.11.2 shall be limited in an amount equal to the initial public offering price of the shares sold by such Holder, unless such liability arises out of
or is based upon willful misconduct by such Holder. 

  

	 	1.11.3.	Each party entitled to indemnification under this Section 1.11 (the “Indemnified Party”) shall give notice to the party required to provide
indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such claim
or any litigation resulting therefrom and enter into any settlement thereof, subject to the Indemnified Party’s consent (which shall not be unreasonably withheld); provided that counsel for the Indemnifying Party, who shall conduct the defense
of such claim or litigation, shall be approved by the Indemnified Party (whose approval shall not unreasonably be withheld), and the Indemnified Party may participate in such defense at such party’s expense, and provided further that the
failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this Section 1.11 unless the failure to give such notice is materially prejudiced to an Indemnifying
Party’s ability to defend such action; and provided further, that the Indemnifying Party shall not assume the defense for matters as to which there is a conflict of interest or separate and different defenses in which case the Indemnified
Party’s costs of defense including reasonable fees of separate legal counsel shall be borne by the Indemnifying Party. No Indemnifying Party in the defense of any such claim or litigation shall, except with the consent of each Indemnified
Party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim
or litigation. 

  
 - 7 -

	 	1.12.	Information by Holder 

 The Holder or Holders of Registrable Securities included in any registration shall furnish to the Company such information regarding such Holder or Holders, the Registrable Securities held by them and the
distribution proposed by such Holder or Holders as the Company may request in writing and as shall be required in connection with any registration, qualification or compliance referred to in this Section 1. 

 

	 	1.13.	Rule 144 Reporting  

  

	 	1.13.1.	With a view to making available the benefits of certain rules and regulations of the Securities Exchange Commission (“SEC”) that may at any time permit
the sale of the Registrable Securities to the public without registration, after such time as a public market exists for the Company’s ordinary shares, the Company agrees to use its best efforts to: 

 

	 	1.13.1.1.	Make and keep public information available, as those terms are understood and defined in Rule 144 under the Securities Act, at all times after the effective date that
the Company becomes subject to the reporting requirements of the Securities Act or the Securities Exchange Act of 1934, as amended; 

  

	 	1.13.1.2.	File with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Securities Exchange Act of 1934, as
amended (at any time after it has become subject to such reporting requirements). 

  

	 	1.14.	Transfer of Registration Rights and other Rights. The rights to cause the Company to register Registrable Securities and any other rights afforded to the
Holders pursuant to this Agreement may be assigned, in whole or in part, to any transferee or assignee of a Holder solely in connection with any transfer or assignment of Registrable Securities or Securities exchangeable or convertible into
Registrable Securities held by such Holder effected in accordance with the Company’s Articles of Association, and provided that such transferee or assignee agrees in writing to be bound by and subject to the terms and conditions of this
Agreement. 

  

	 	1.15.	Market Stand Off. In any registration of Registrable Securities or in the Company’s IPO, the Holders agree to abide by a customary “lock
up” period of up to one hundred and eighty (180) days if so required by the underwriter in such registration, provided that such obligation shall also apply to the officers, directors, and significant shareholders of the Company. For the
purpose of this Section 1.15, the term “significant shareholders” shall mean a holder of at least 10% of the Company’s issued and outstanding share capital on a fully diluted basis immediately prior to such registration.

  
 - 8 -

	 	1.16.	Termination of Registration Rights. Any rights to registration under this Section 1 shall terminate upon the fifth anniversary of the closing of the
Company’s IPO. 

  

	2.	INFORMATION RIGHTS 

Without derogating from any of the rights the Holders might have under the Israeli Companies Law, 1999, until the closing of an IPO, the
Company shall prepare and provide to the Holders the following documents: 
  

	 	2.1.	Within seventy five (75) days after the end of each fiscal year of the Company, annual financial statements (including an audited balance sheet of the Company as
of the end of such year, and audited statements of income and statements of cash flow of the Company for such year), audited by a firm of Independent Certified Public Accountants in the State of Israel who are members of the Israeli Institute of
Certified Public Accountants, and accompanied by an opinion of such firm, which opinion shall state that such financial statements (including the balance sheet and statements of income and cash flow have been prepared in accordance with Israeli GAAP
applied on a basis consistent with that of the preceding fiscal year, and present fairly and accurately the financial position of the Company as of their date, and that the audit by such accountants in connection with such financial statements has
been made in accordance with generally accepted auditing standards; and 

  

	 	2.2.	Within forty five (45) days after the end of each quarter of each fiscal year of the Company, unaudited but reviewed financial statements (including a balance
sheet of the Company as at the end of each such period and unaudited statements of income and cash flow of the Company for such period), accompanied by a brief confidential overview of the operations of the Company for the ended quarter as
shall be prepared by the management of the Company. 

 The information provided by the Company under this
Section 2 shall be held by all recipients in strictest confidence. 
  

	 	2.3.	Accounting. The Company will maintain a system of accounting established and administered in accordance with GAAP consistently applied, and will set aside on its
books all such proper reserves as shall be required by GAAP. 

  

	3.	CANCELLATION OF PREVIOUS AGREEMENTS 

  

	 	3.1.	Cancellation of Voting Agreement. The Company and those of the undersigned which are also parties to that certain Amended & Restated Voting
Agreement dated January 11, 2004 (the “Voting Agreement”), do hereby cancel the Voting Agreement, pursuant to section 5 of the Voting Agreement, and declare that upon their signature hereunder, the Voting Agreement shall have
no force and effect. 

  

	 	3.2.	Cancellation of Certain Sections of Loan Agreements. 

  

	 	3.2.1.	 The Company and those of the undersigned which are also parties to that certain AMENDED AND RESTATED CONVERTIBLE LOAN AGREEMENT dated
July 20, 2003 (the “First Loan Agreement”) and/or that certain Amendment to the amended and restated Convertible Loan Agreement dated December 12, 2003 (the “Second Amendment of the First Loan
Agreement”), do hereby agree to the cancellation of Sections 4 (Loan Repayment), 6 (Business Plan), 7 (Conversion), 

  
 - 9 -

	 	
8 (Protection of Lenders’ Interests), 9 (Board of Directors) and 12 (Information Rights) of the First Loan Agreement and to the cancellation of Section 5 (the
Loan Repayment) of the Second Amendment of the First Loan Agreement, and declare that upon their signature hereunder, such provisions shall have no force and effect. 

 

	 	3.2.2.	 The Company and those of the undersigned which are also parties to that certain Convertible Bridge Loan agreement with Options dated January 18,
2005 (the “2005 Convertible Bridge Loan”), as amended, do hereby agree to the cancellation of Sections 4.2 (Automatic Conversion of Loan in the event of no Next Equity Financing (at the Final Date)), 5 (Repayment), 6
(Exit Events), and 7 (Adjustments) of the 2005 Convertible Bridge Loan and Section 5.2 (Additional Conversion Alternative in the event of an Automatic Conversion of the Loan upon a “Next Equity Financing”) of the
1st Amendment to the Convertible Bridge Loan Agreement
dated January 27, 2005, and declare that upon their signature hereunder, such provision shall have no force and effect. 

  

	4.	BRING ALONG 

 The
Shareholders hereby give their consent to the Bring Along provision set forth in Article 70 of the Company’s Amended Articles attached as Exhibit 6.1.1(a) of the Series B Share Purchase Agreement. 

 

	5.	GENERAL PROVISIONS 

  

	 	5.1.	Entire Agreement. This Agreement constitutes the full and entire understanding and agreement between the parties with regard to the subject matters hereof
and thereof and supersedes any prior understanding or agreement between the parties with regard to the subject matters hereof, including the Former Amended RRA. 

 

	 	5.2.	Validity. This Agreement shall enter into effect subject to and upon fulfillment of each of the following cumulative conditions: (i) receipt of the
signatures of the Required Majority that is required in order to amend the Former RRA and replace it in its entirety with this Agreement; (ii) receipt of the signatures of the majority that is required in order to cancel the Voting Agreement as
set forth in Section 3.1 above; (iii) receipt of the signatures of the majority that is required in order to cancel certain provisions of the First Loan Agreement and of the Second Amendment of the First Loan Agreement as set forth in Section
3.2.1 above; (iv) receipt of the signatures of the majority that is required in order to cancel a certain provision of the 2005 Convertible Bridge Loan as set forth in Section 3.2.2 above; and (v) consummation of the First Closing of the
Series B Share Purchase Agreement (as such term is defined therein). 

  

	 	5.3.	Amendment of Rights. Any provision of this Agreement may be amended and the observance thereof may be waived (either generally or in
a particular instance and either retroactively or prospectively), only with the written consent of the Company and holders of at least 60% (sixty percent) of Registrable Securities then outstanding or issuable upon conversion of Series B-1 Preferred
Shares, Series B Preferred Shares, Series A Preferred Shares, and/or Ordinary-1 Shares then outstanding. Any amendment or waiver affected in accordance with this Section 5.3 shall be binding upon each Holder, each permitted successor or
assignee of the Holder and the Company. 

  
 - 10 -

	 	5.4.	Joining Parties. It is hereby agreed that any New Investor (as defined in the Series B Share Purchase Agreement) participating in the Second Closing of the
Series B Share Purchase Agreement shall become a party to this Agreement, and a “Shareholder” for all intents and purposes hereunder, by singing the Joinder Agreement attached as Exhibit 3.4 of the Series B Share Purchase Agreement.

  

	 	5.5.	Notices. All notices and other communications required or permitted hereunder to be given to a party to this Agreement shall be in writing and shall be
telecopied or mailed by registered or certified mail, postage prepaid, or otherwise delivered by hand or by messenger, addressed to such party’s address as set forth below or at such other address as the party shall have furnished to each other
party in writing in accordance with this provision: 

 if to the Company: as set forth in the Preamble hereto;

 if to the Shareholders: as set forth in Schedule A hereto. 

or such other address with respect to a party as such party shall notify each other party in writing as above provided. Any notice sent
in accordance with this Section 5.5 shall be considered as having reached its destination, if it was delivered by hand, at the time of its delivery; if it was sent by registered mail, within 96 hours from the time it was so dispatched; and if it was
sent by facsimile, within 24 hours from the receipt of the confirmation of proper transmission of the notice. 
  

	 	5.6.	Governing Law; Jurisdiction. This Agreement shall be governed by and construed according to the laws of the State of Israel. Any dispute arising under or
in relation to this Agreement shall be resolved exclusively by the competent courts of Tel-Aviv Jaffa, Israel, and the parties hereto irrevocably submit to the exclusive jurisdiction of such courts for such purposes. 

 

	 	5.7.	Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, then such provision(s) shall be excluded from
this Agreement and the balance of this Agreement shall be interpreted as if such provision(s) were so excluded and shall be enforceable in accordance with its terms. 

 

	 	5.8.	Third Parties. Nothing in this Agreement, express or implied, is intended to confer upon any person, other than the parties hereto and their permitted
successors and assigns, any rights or remedies under or by reason of this Agreement. 

  

	 	5.9.	Counterparts. This Agreement may be executed in facsimile counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. 

  
 - 11 -

 IN WITNESS WHEREOF, the parties hereto have executed this Investors Rights Agreement as of
the date and year first above written. 
  

							
	 The Company:
	 		 	EVOGENE LTD., by:
			
		 		 	 /s/ Ofer Haviv /s/ Hagai Karchi

		 		 	Name:	 	 Ofer Haviv

		 		 	Title:	 	 CEO

	 The Shareholders:
	 		 		 	
			
		 		 	KADIMA HIGH-TECH LTD., By:
			
		 		 	 /s/ Illegible

		 		 	Name:	 	 Kadima High-Tech Ltd.

		 		 	Title:	 	 Kadima High-Tech Ltd.

			
		 		 	EPIONE BIOINVESTMENT I L.P., By:
			
		 		 	 /s/ Eric Messika

		 		 	Name:	 	 Eric Messika

		 		 	Title:	 	 General Partner

			
		 		 	EPIONE BIOINVESTMENT II L.P., By:
			
		 		 	 /s/ Eric Messika

		 		 	Name:	 	 Eric Messika

		 		 	Title:	 	 General Partner

			
		 		 	HACKMEY JOSEPH
			
		 		 	 /s/ Hackmey Joseph
            

			
		 		 	PIERRE SCHNEIDER
			
		 		 	 /s/ Pierre Schneider

  
 - 12 -

			
	GRYP INVESTMENTS LTD. by:
	
	 /s/ Illegible

	Name:	 	  

	Title:	 	  

	
	PETER WEINREB
	
	  

	
	HUNZA VENTURES S.A. by:
	
	 /s/ Miemile Vogt

	Name:	 	 Miemile Vogt

	Title:	 	 Director

	
	MARK GELFAND
	
	 /s/ Mark Gelfand

	
	COMPUGEN LTD. by:
	
	 /s/ Amos Reltzer

	Name:	 	 Amos Reltzer

	Title:	 	 General Counsel

	
	DR. HAGAI KARCHI
	
	 /s/ Hagai Karchi

	
	DR. RAFAEL MEISSNER
	
	 /s/ Rafael Meissner

  
 - 13 -

			
	LEON RECANATI
	
	 /s/ Leon Recanti

	
	ROBERT H. ASHER
	
	  

	
	CAREMI PARTNERS LTD., By:
	
	 /s/ Steven Ruchefsky

	Name:	 	 Steven Ruchefsky

	Title:	 	 President

	
	MARTIN GERSTEL
	
	 /s/ Martin Gerstel

	
	SHOMAR CORPORATION, By:
	
	 /s/ Marianne Janowsky

	Name:	 	 Marianne Janowsky

	Title:	 	 Chairman

	
	UZI ZUCKER
	
	 /s/ Uzi Zucker

	
	GKW UNIFIED HOLDINGS LLC, By:
	
	 /s/ Kurt Tomitz

	Name:	 	 Kurt Tomitz

	Title:	 	 Chief Financial Officer

	
	SOPHIE DULAC
	
	  

  
 - 14 -

			
	PATRIMOINE INTERNATIONAL HOLDINGS S.A., By:
	
	  

	Name:	 	  

	Title:	 	  

	
	HUGUES D’HAUSSONVILLE
	
	  

	
	PAUL NIZARD
	
	  

	
	YOEL GUILATT
	
	 /s/ Yoel Guilatt

	
	TZINA NIHUL VE YIZUM LTD., By:
	
	 /s/ Illegible

	Name:	 	  

	Title:	 	  

	
	ARISTO VENTURES LTD., By:
	
	 /s/ Meir Leshem

	Name:	 	 Meir Leshem

	Title:	 	 CEO

	
	FRED CRAVES
	
	 /s/ Fred Craves

	
	MORDECHAI SEGAL
	
	  

  
 - 15 -

			
	GOLD POINT INVESTMENT INC.
	
	 /s/ S.N. Ariav

	Name:	 	 S.N. Ariav

	Title:	 	 Attorney-in-Fact

	
	RAMI HAVIV
	
	  

	
	REICH EINAT
	
	 /s/ Einat Reich

	
	GOLDBERG PNINA
	
	 /s/ Pnina Goldberg

	
	BAKER LEONARD
	
	 /s/ G. Leonard Baker

	
	FRIEDKIN MORTON
	
	 /s/ Morton Friedkin

	
	STAFFORD ROBERT
	
	 /s/ Robert Stafford

	
	SHAY FRIEDMAN
	
	 /s/ Shay Friedman

	
	DANNY FLEISHER
	
	 /s/ Danny Fleisher

  
 - 16 -

			
	GAD NOIK
	
	 /s/ Gad Noik

	
	ZERAIM GEDERA LTD., By:
	
	  

	Name:	 	  

	Title:	 	  

  
 - 17 -

 Schedule A – Shareholders’ Addresses 

 

					
	 	  	 Shareholder
	  	 Address

	 1.
	  	Kadima High-Tech Ltd. (as trustee)	  	 c/o Kadima High-Tech Ltd.
 10
Oceanus Building

10th Floor, Suit 1005
 Herzelia Pituach 46555
 Attn: Yossi Ben-Yoseph
 E-mail: yossi@kadimainv.com

 
 With a copy to:
 Gornitzky & Co.
 45 Rothschild Blvd.
 Tel Aviv, 65784
 Fax: +972-3-560-6555
 E-mail: gross@Gornitzky.co.il
 Attn: Dubi Gross, Adv.

			
	 2.
	  	Epione BioInvestment I L.P.	  	 c/o Epione BioInvestment I L.P.

7 Rival St.
 Beit Amgar, 2nd Floor
 Tel-Aviv 67778
 Attn: Dr. Eric Messika
 E-mail: eric@coronis-partners.com
  
 With a copy to:
 Baratz, Horn & Co.
 1 Azrieli Center, Round
 Tower, 18th Floor
 Tel
Aviv 67021, Israel
 Tel: 972-3-6073766

Fax: 972-3-6073778
 E-mail:
y.horn@bar-law.com
 Attn: Yuval Horn, Adv.

			
	 3.
	  	Epione BioInvestment II L.P.	  	 c/o Epione BioInvestment II L.P.

7 Rival St.
 Beit Amgar, 2nd Floor
 Tel-Aviv 67778
 Attn: Dr. Eric Messika
 E-mail: eric@coronis-partners.com
  
 With a copy to:
 Baratz, Horn &
Co.

  
 - 18 -

					
		  		  	 1 Azrieli Center, Round
 Tower,
18th Floor

Tel Aviv 67021, Israel
 Tel:
972-3-6073766
 Fax: 972-3-6073778

E-mail: y.horn@bar-law.com
 Attn: Yuval Horn,
Adv.

			
	 4.
	  	Hackmey Joseph	  	 [* * *]
 [* *
*]

			
	 5.
	  	Pierre Schneider	  	 [* * *]
 [* * *]

[* * *]

			
	 6.
	  	GRYP Investments Ltd.	  	 8 Hamenofim st. Beit Ofek,

4th floor
 Hertzeliya Pituach
 office: 972-9-9725699
 fax: 972-9-972-5606

			
	 7.
	  	Peter Weinreb	  	 [* * *]
 [* * *]

[* * *]

			
	 8.
	  	Leon Recanati	  	 [* * *]
 [* * *]

[* * *]
 Fax: [* * *]

Tel: [* * *]

			
	 9.
	  	Robert H. Asher	  	 [* * *]
 [* * *]

Fax: [* * *]

        [* * *]
 Tel: [* * *]

			
	 10.
	  	Caremi Partners Ltd.	  	 Two American Lane
 Greenwich CT
06836
 Fax: (203)-8627146
 Tel:
(203)-8614829

			
	 11.
	  	Martin Gerstel	  	 [* * *]
 [* * *]

[* * *]

			
	 12.
	  	Shomar Corporation	  	 2 Bradford Road
 Plainview, New
York 11803
 U.S.A.
 Fax:
(516)-9357836
 Tel: (516)-9357848

			
	 13.
	  	Uzi Zucker	  	 c/o Bear, Stearns & Co. Inc.

383 Madison Ave. –
40th Floor

New York, NY 10179
 Fax: (212)-2729318

Tel: (212)-2723745

  
 - 19 -

					
	 14.
	  	GKW Unified Holdings LLC	  	 360 North Crescent Drive

Beverly Hills, California
 USA
90210-3818
 Fax: (310)-2815831
 Tel:
(310)-4995432

			
	 15.
	  	Sophie Dulac	  	 [* * *]
 [* * *]

[* * *]
 Tel: [* * *]

			
	 16.
	  	Patrimoine International Holdings S.A.	  	 3 Rue Guillaume Kroll
 L –
1882 Luxembourg
 Fax: (352)-40-45-48

Tel: (352)-40-63-55

			
	 17.
	  	Hugues d’Haussonville	  	 240 Rue de Rivoli
 75001 Paris,
France
 Fax: (0033)-142961688
 Tel:
(0033)-142961072

			
	 18.
	  	Paul Nizard	  	 [* * *]
 [* * *]

Fax: [* * *]
 Tel: [* *
*]

  
 - 20 -

					
	 19.
	  	Yoel Guilatt	  	 [* * *]
 [* * *]

Fax: [* * *]
 Tel: [* * *]

			
	 20.
	  	Tzina Nihul Ve Yizum Ltd.	  	 9 Hamiktzoa St.
 Tel
Aviv
 Israel
 Fax:
03-6874504
 Tel: 03-5372225

			
	 21.
	  	Aristo Ventures Ltd.	  	 5/39 Fishman Maimon St.
 Tel
Aviv
 Israel
 Fax:
03-5270789
 Tel: 03-5224878

			
	 22.
	  	Mordechai Segal	  	 [* * *]
 [* * *]

[* * *]
 Tel: [* * *]

Fax: [* * *]
 Tel [* * *]: [* *
*]

			
	 23.
	  	Fred Craves	  	 [* * *]
 [* * *]

[* * *]
 Tel: [* * *]

Fax: [* * *]

			
	 24.
	  	Gold Point Investment Inc.	  	 Gold Point Investment Inc.
 c/o
Sucre, Arias, Castro & Reyes
 Edificio Sucre
 Bella Vista, Calle 48
 P.O Box 6277
 PA-Panama 5
  

  
 - 21 -

					
		  		  	 Mailing address:
  

Gold Point Investment Inc.
 c/o Dr. Peter
Kienast
 Bar & Karrer

Seefeldstrasse 19
 CH-8024 Zurich

Switzerland

			
	 25.
	  	Rami Haviv, Adv. (as trustee for Gabi Gonen Levi)	  	 [* * *]
 [* * *]

[* * *]
  
 With a copy to:
 [* * *]

			
	 26.
	  	Reich Einat	  	 [* * *]
 [* * *]

[* * *]

			
	 27.
	  	Goldberg Pnina	  	 [* * *]
 [* * *]

[* * *]

			
	 28.
	  	The Baker Revocable Trust U/A/D 2/3/03	  	 755 Page Mill Road, Suite A-200

Palo Alto, CA 94304
 U.S.A.

Tel: 650-493-5600
 Fax:
650-858-1854

			
	 29.
	  	Friedkin Morton	  	 [* * *]
 [* * *]

[* * *]
 Tel: [* * *]

Fax: [* * *]

  
 - 22 -

					
	 30.
	  	Stafford Robert	  	 Stafford capital management

222 Kearny Street, Suite 410
 San Francisco, Ca
94108
 U.S.A.
 Fax:
415-362-3048

			
	 31.
	  	Shay Friedman	  	 [* * *]
 [* * *]

[* * *]

			
	 32.
	  	Danny Fleisher	  	 [* * *]
 [* * *]

[* * *]

			
	 33.
	  	Gad Noik	  	 [* * *]
 [* * *]

[* * *]

			
	 34.
	  	Zeraim Gedera Ltd.	  	 P.O. Box 103,
 Gedera
70075,
 Israel

			
	 35.
	  	 Compugen Ltd.
	  	 72 Pinchas Rozen St.,
 Tel Aviv
69512
 Israel

  
 - 23 -

					
	 36.
	  	 Rafael Meisner
 (Including in
respect of any shares beneficially owned by Mr. Meisner and held in trust by Debbie Goodman, Adv.)
	  	 [* * *]
 [* * *]

[* * *]

			
	 37.
	  	 Hagai Karchi
 (Including in
respect of any shares beneficially owned by Mr. Karchi and held in trust by Debbie Goodman, Adv.)
	  	 [* * *]
 [* * *]

[* * *]

			
	 38.
	  	 Hunza Ventures S.A.
	  	 Hunza Ventures SA
 Boulevard
Joseph II 40
 1840 Luxembourg
 Tel 352
45 31 31
 Fax 352 45 31 33

			
	 39.
	  	Mark Gelfand	  	 [* * *]
 [* *
*]
 [* * *]
 [* *
*]

  
 - 24 -EX-10.18

 Exhibit 10.18 

PUT OPTION AGREEMENT 

THIS PUT OPTION AGREEMENT (“Agreement”) is dated as of 27 October 2013 (the “Signing Date”), by and
between Monsanto Company, a Delaware corporation (“Monsanto”), and Evogene Ltd., an Israeli company (“Evogene”). 

WHEREAS, Evogene is a publicly-traded company whose securities are listed for trade on the Tel Aviv Stock Exchange Ltd. (hereinafter the
“TASE”); and 
 WHEREAS, Monsanto and Evogene are parties to that certain Amended and Restated Collaboration Agreement (as
defined below), and contemporaneously with the signing of this Agreement are entering into an amendment to the Amended and Restated Collaboration Agreement (the “2nd Amended and Restated
Collaboration Agreement”); and 
 WHEREAS, the Parties have agreed that Monsanto shall grant Evogene the New Put Option (as defined
below), entitling Evogene to require Monsanto to invest US$12,000,000 in Evogene in consideration for Ordinary Shares of Evogene, exercisable at the times, and subject to additional terms and conditions, as set forth in this Agreement; and 

WHEREAS, Monsanto and Evogene are parties to that certain Share Purchase Agreement dated 27 August 2008, as amended on September 21,
2011, November 14, 2011 and November 28, 2011 (collectively, the “Share Purchase Agreement”); and 

WHEREAS, the Parties have also agreed to terminate the Original New Put Option (as defined below) set forth in the Share Purchase Agreement,
and instead to increase the royalties rate and milestone payments to which Evogene was entitled pursuant to the Amended and Restated Collaboration Agreement, as set forth in the 2nd Amended and
Restated Collaboration Agreement. 
 NOW, THEREFORE, it is agreed by and between the parties as follows: 

 

	1.	Preamble, Appendices and Interpretation  

  

	1.1	The preamble to this Agreement constitutes an integral part hereof and is to be read as one with the remaining clauses thereof. 

  

	1.2	In this Agreement, unless otherwise expressly stated, the terms set out below shall bear the meaning appearing opposite them: 

  

	 	a.	“Amended & Restated Collaboration Agreement” – the Amended & Restated Collaboration Agreement between the parties dated November 28, 2011, relating to developing transgenic
yield and stress traits in certain agricultural crops. 

  

	 	b.	 “Material Announcement” – means any earnings release or any public announcement for which Evogene would be required to file
(i) an immediate report under Chapter C of the Israeli Securities Regulations (Periodic and Immediate Statements) 5730-1970, other 

	 	
than immediate reports (the “Excluded Reports”) filed pursuant to sections 31 (to the extent such report relates to option exercises by directors, employees or service providers), 31A,
31B, 31E, 32 (to the extent such report relates to option exercises by directors, employees or service providers), 33 (other than regarding changes as a result of which a person became the holder of an interest in a control bloc), 34 (other than
regarding a change in the Company’s CEO), 35, 36B (to the extent that such report relates to an Annual Meeting other than an Annual Meeting for which an item is included on the agenda for which Evogene otherwise would have to convene an
extraordinary general meeting if it was not able to address the issue at the annual meeting), 36C (to the extent that such report relates to an Annual Meeting other than an Annual Meeting for which an item is included on the agenda for which Evogene
otherwise would have to convene an extraordinary general meeting if it was not able to address the issue at the annual meeting) or 36D (to the extent that such report relates to an Annual Meeting other than an Annual Meeting for which an item is
included on the agenda for which Evogene otherwise would have to convene an extraordinary general meeting if it was not able to address the issue at the annual meeting) of the Israeli Securities Regulations (Periodic and Immediate Statements)
5730-1970, or (ii) if the Ordinary Shares are then traded on the New York Stock Exchange (or any other United States stock exchange), a current report under the Securities Exchange Act of 1934, as amended, or the rules promulgated thereunder,
other than current reports the subject matter of which would require filing an Excluded Report. 

  

	 	c.	“Maximum Exercise Price” – means US$ 17.00. 

  

	 	d.	“Minimum Exercise Price” – means US$ 7.00. 

  

	 	e.	“Exercise Date” – the date on which Evogene delivers the Exercise Notice (as defined in clause 2(b)) to Monsanto. 

 

	 	f.	 “New Put Option Exercise Price” – means (i) the average closing price of the Ordinary Shares on the TASE, in U.S.$, on the
30 trading days immediately prior to the Exercise Date or (ii) if, on the Exercise Date, the Ordinary Shares are already traded on the New York Stock Exchange (or any other United States stock exchange), then the New Put Option Exercise Price
will be the average closing price (in U.S.$) of the Ordinary Shares on the New York Stock Exchange (or such other United States stock exchange, as applicable) on the 30 trading days (on the relevant stock exchange) immediately prior to the Exercise
Date; provided, however, that the New Put Option Exercise Price, whether calculated based on the TASE closing price or the relevant U.S. stock exchange closing price, shall not be higher than the Maximum Exercise Price or lower than the Minimum
Exercise Price. 

  
 -2- 

	 	
For purposes of clause (i), the New Put Option Exercise Price will be determined by converting the NIS closing price of the Ordinary Shares on the TASE on each of such 30 trading days into U.S.$,
based on the exchange rate reported by the Bank of Israel on each such day, and then calculating the average of such U.S.$ closing prices. 

  

	 	g.	“Ordinary Shares” – means Ordinary Shares of Evogene, having a par value of NIS 0.01 each, or such other par value as shall be in effect at the relevant time, if prior thereto Evogene
effects a share split or reverse share split of its Ordinary Shares. 

  

	 	h.	“Put Option Investment Amount” – US$ 12,000,000, as may be reduced in accordance with clause 3 below. 

  

	 	i.	“Regulations” – the regulations that were promulgated under the Securities Law. 

  

	 	j.	“Securities Act” – the U.S. Securities Act of 1933, as amended. 

  

	 	k.	“Securities Law” – the Israeli Securities Law -1968. 

  

	 	l.	“U.S. IPO” – an initial public offering of Evogene securities in the United States. 

  

	2.	New Put Option 

  

	 	a.	Subject to Evogene issuing to Monsanto a letter from Evogene’s Chief Executive Officer confirming that the Board of Directors of Evogene has approved the grant of the New Put Option to Monsanto and a letter from
the Chairman of Evogene’s Board of Directors pursuant to Section 282 of the Israeli Companies Law – 1999 confirming that all approvals required by Evogene for the grant of the New Put Option have been obtained, Monsanto hereby
irrevocably grants Evogene an option (hereinafter the “New Put Option”) pursuant to which Evogene may issue to Monsanto such number of Ordinary Shares as obtained by dividing the Put Option Investment Amount by the New Put Option
Exercise Price (hereinafter the “New Put Option Shares”), at a price per New Put Option Share of the New Put Option Exercise Price and for an aggregate consideration in the amount of the Put Option Investment Amount, that will be
paid by Monsanto in US dollars. Partial exercise of the New Put Option shall be subject to the written consent of the Parties. Monsanto agrees that it shall not transfer any of the New Put Option Shares during the 45-day period following purchase of
the New Put Option Shares pursuant to the New Put Option. The 45-day holding period described in this clause (a) above shall not apply in the event of an exercise of the option immediately prior to a COC Event (as defined below) of Evogene.

  

	 	b.	 Subject to Evogene issuing to Monsanto a letter from Evogene’s Chief Executive Officer confirming that the Board of Directors of Evogene has
approved the issuance of the New Put Option Shares (as defined below) to Monsanto and a letter from the 

  
 -3- 

	 	
Chairman of Evogene’s Board of Directors pursuant to Section 282 of the Israeli Companies Law – 1999 confirming that all approvals required by Evogene for the issuance of the New
Put Option Shares have been obtained, exercise of the New Put Option may be made by Evogene at any time, but subject to clause 2(c), commencing on the earlier of: (i) 180 days after the closing of a U.S. IPO (the “IPO Exercise
Trigger Date”) or (ii) February 1, 2016; and Evogene’s right to exercise the New Put Option shall terminate on the earlier of: (x) six (6) months after the IPO Exercise Trigger Date or (y) July 15,
2016 (inclusive). For the avoidance of doubt, the New Put Option cannot be exercised after, and shall automatically terminate as of 11:59 p.m. Israeli time on, July 15, 2016. The New Put Option may be exercised by Evogene during the relevant
period by notice in writing of Evogene to Monsanto (hereinafter the “Exercise Notice”). 

  

	 	c.	At any time that Evogene makes a Material Announcement, Evogene’s right to exercise the New Put Option shall be suspended for at least three (3) trading days. Evogene shall compare the closing trading price on
the day of the Material Announcement to the closing trading price on the third (3rd) trading day after the Material Announcement. If the difference between the two closing trading prices is
five percent (5%) or more, Evogene’s right to exercise the New Put Option shall be suspended until the opening of trading on the fifteenth (15th) trading day after the date of the
Material Announcement. For the purposes of this clause 2(c), (i) if the Ordinary Shares are not then traded on the New York Stock Exchange (or any other United States stock exchange), “trading day” shall mean a trading day of the TASE
and (ii) if the Ordinary Shares are then traded on the New York Stock Exchange (or any other United States stock exchange), “trading day” shall mean a trading day of relevant United States stock exchange on which the Ordinary Shares
are traded. 

  

	 	d.	Immediately after delivery of the Exercise Notice, Evogene will proceed to obtain the approval of the TASE to issue and list the New Put Option Shares for trading (the “TASE Approval”). Additionally, if
the Ordinary Shares are not listed on a U.S. exchange at such time, Evogene will proceed to publish an immediate report (‘current report’) pursuant to the Securities Law Regulations (Private Offering of Securities in a Listed Company),
2001 (the “Private Offering Regulations”) and, if the Ordinary Shares are listed on a U.S. exchange at such time, Evogene shall submit information relating to the Exercise Notice on Form 6-K to the U.S. Securities and Exchange
Commission. 

 Upon receipt of the Exercise Notice by Monsanto, Evogene and Monsanto shall each use commercially reasonable
efforts to complete the Premerger Confirmation (as defined below) as soon as reasonably practicable and shall provide the other party with all information reasonably required in order to assist the other party to determine whether there are any
premerger notification obligations under applicable competition laws or orders, and if required by such laws or orders, to file a premerger notification. The receiving party shall keep any such information provided in strict confidence, shall use it
solely for the purpose of the above purposes, and to the extent practicable shall obtain confidential treatment of such information by the authorities. Each party shall be responsible for determining any applicable premerger notification obligations
triggered by such party’s business or other circumstances and informing the other party of such obligations. 

  
 -4- 

	 	e.	It is hereby agreed that the consummation of the transactions required by the exercise of the New Put Option, including the issuance of the New Put Option Shares under this Agreement, is subject to: (i) the TASE
Approval, and (ii) Evogene and Monsanto confirming, each with respect to any obligations triggered by such party’s business or other circumstances, the absence or completion of any premerger notification obligations or investigations under
applicable competition laws or orders (the “Premerger Confirmation”). 

  

	 	f.	The parties will, within four (4) US business days after the later of (i) the date of receiving the TASE Approval and (ii) the date of the Premerger Confirmation, convene by teleconference, facsimile and
electronic mail communication, and take the following action: 

  

	 	i.	Monsanto will furnish to Evogene details of the account in which the New Put Option Shares will be deposited. 

  

	 	ii.	Monsanto will wire transfer the New Put Option Investment Amount to Evogene’s bank account as detailed below or such other bank account as shall be detailed in the Exercise Notice: 

First International Bank 
 Swift
Code: FIRBILITXXX 
 Ramat Hachayal Branch, Branch no. 121 

Payable to :Evogene Ltd. 

Account no. 600555 
 Bank
telephone number: +972-3-768-0200
 Bank facsimile number: +972-3-649-5988 

 

	 	iii.	Evogene shall deliver to Monsanto the copy of a share certificate registered in the name of Evogene’s nominees company at such time representing the New Put Option Shares, unless the Ordinary Shares are then
registered on the New York Stock Exchange (or such other United States stock exchange, as applicable) in which case the share certificate shall be registered in the name of the nominee designated by Monsanto. 

 

	 	iv.	Upon receipt of the New Put Option Investment Amount, Evogene undertakes to deliver to its nominees company the share certificate and other documentation necessary to enable the trade of the New Put Option Shares.

  

	 	g.	 In the event that either Evogene or Monsanto is not able, despite best efforts to do so, to provide the Premerger Confirmation within 45 days of
receipt of the Exercise Notice by Monsanto (the “Waiting Period”), then Monsanto shall not be required to purchase the New Put Option Shares, and instead, within 7 days from the end of the

  
 -5- 

	 	Waiting Period Monsanto shall pay to Evogene an amount equal to the Put Option Investment Amount less the Option Exercise Price (as defined below) (as converted from New Israeli Shekels to US Dollars on the date of
payment) in exchange for an option to acquire all, but not less than all, of the applicable New Put Option Shares (the “Option”) for an aggregate exercise price in the amount of the aggregate par value of the New Put Option Shares
(the “Option Exercise Price”). Such option shall: (i) be freely transferrable by Monsanto (subject only to applicable securities laws); (ii) be exercisable by Monsanto (or its transferee) at any time, subject to the
limitations below and subject to Monsanto first determining whether there are any premerger notification obligations under applicable competition laws or orders, and if required by such laws or orders, after filing a premerger notification and
receiving any permits that may be required under applicable competition laws or orders; (iii) require Evogene to provide at least 14 days advance notice to Monsanto of a sale of Evogene in which all shareholders (including Monsanto after
exercise) are required to sell all shares of Evogene or a merger in which Evogene is not the surviving entity or the liquidation of Evogene, and Monsanto hereby undertakes to maintain all non-public information provided by Evogene in strictest
confidence (each a “COC Event”); (iv) require Monsanto (or its transferee) to exercise the Option by not later than 4 days prior to a COC event (provided such 10 days’ notice is given), which exercise may be conditioned
upon the Closing of such COC Event, or forfeit the right to purchase the New Put Option Shares; (v) shall expire upon the earlier of: (x) closing of a COC Event; or (y) 10 years from the date of the Option, and (vi) provide for
customary adjustments to the number of New Put Option Shares and the Option Exercise Price for stock splits, stock dividends, repurchases of stock at above market prices and similar events. The 45-day holding period described in clause
(a) above shall not apply in the event of an exercise of the Option immediately prior to a COC Event. 

  

	 	h.	Evogene shall use reasonable efforts to assist Monsanto in obtaining information and assistance reasonably necessary for Monsanto to make any filings with applicable taxing authorities that may be necessary as a result
of Monsanto’s direct or indirect ownership of Evogene, including, without limitation, filings to claim tax-credits under Section 902 of the U.S. Internal Revenue Code of 1986, as amended; provided that, to the extent Evogene incurs an
expense to a third party in complying with this covenant such expense will be borne by Monsanto. 

  

	3.	U.S. IPO 

 If prior to February 1, 2016 Monsanto purchases, directly or through a
subsidiary, Evogene securities in the framework of a U.S. IPO, then the Put Option Investment Amount will be reduced by the amount actually invested by Monsanto in Evogene in the U.S. IPO. For example: if Monsanto invests in Evogene US$8,000,000 in
a U.S. IPO, then upon such investment the Put Option Investment Amount shall be reduced to US$4,000,000 (US$12,000,000- US$8,000,000= US$4,000,000). 

  
 -6- 

	4.	Exercise Price Adjustments 

 The Maximum Exercise Price and the Minimum Exercise Price,
shall be proportionately adjusted for any increase or decrease in the number of issued Ordinary Shares resulting from a split, reverse split, bonus share issuance, combination of the Ordinary Shares or any other increase or decrease in the number of
issued Ordinary Shares effected without receipt of any consideration by Evogene. Evogene shall notify Monsanto in writing of any such adjustment, within 14 days thereof. 
  

	5.	Termination of the Original New Put Option and of Monsanto’s Right to a Director 

The New Put Option (as defined in the Share Purchase Agreement) previously granted by Monsanto to Evogene pursuant to the Share Purchase
Agreement (the “Original New Put Option”) is hereby terminated in its entirety. 
 Monsanto’s right to nominate a
Director to the Company’s Board of Directors, pursuant to Section 8 of the Share Purchase Agreement, is hereby irrevocably terminated in its entirety. For clarification, notwithstanding the foregoing, commencing upon the Signing Date
Monsanto shall have the right to nominate a non-voting observer to the Company’s Board of Directors, on the terms set forth in Section 8 of the Share Purchase Agreement. 

 

	6.	Representations of Monsanto 

 Monsanto hereby represents and warrants as follows: 

 

	 	a.	It is a public company formed under the laws of the State of Delaware, whose securities are listed for trade on the NY Stock Exchange. 

 

	 	b.	It has the full corporate power and authority to execute and deliver this Agreement and to consummate the transactions contemplated hereby. Monsanto has duly and validly executed and delivered this Agreement, and
assuming compliance by Evogene herewith, this Agreement when executed by Monsanto will constitute valid, binding and enforceable obligations of Monsanto in accordance with its terms. 

 

	 	c.	It has sufficient immediately available funds in cash to pay the Put Option Investment Amount and to satisfy any other obligations hereunder and in connection with the transactions contemplated hereby on the terms and
conditions as set forth herein. 

  

	 	d.	It is aware that the New Put Option Shares will be subject to Section 15 of the Securities Law and the Securities Law Regulations (Details with Regard to Sections 15A to 15C of the Law), 2000, which imposes certain
restrictions in respect of the tradability of the New Put Option Shares. 

  

	 	e.	On the date of this Agreement, it does not hold any securities of Evogene, directly or indirectly, other than those securities listed on the immediate report with respect to interested parties’ holdings, last filed
by Evogene with the TASE prior to the Signing Date. 

  
 -7- 

	 	f.	No written or oral agreement or voting agreement exists between Monsanto and any of the holders of the other securities of Evogene or any other person or entity concerning their rights and/or holdings in Evogene.

  

	 	g.	Except for the Premerger Confirmation which is required in the event Evogene exercises the New Put Option, no consents, approvals, authorizations or permits are required in connection with the consummation by Monsanto
of the transactions contemplated by this Agreement. 

  

	 	h.	Monsanto will, whenever necessary, deliver to Evogene in English all data and information that is required for the purpose of publishing immediate reports pursuant to the Private Offering Regulations and the Securities
Law Regulations (Periodic and Immediate Statements), 1970; provided, however, that Evogene shall provide reasonable assistance to Monsanto should Monsanto wish to approach a court or applicable regulatory authority to determine whether such
additional information is required to be submitted and/or whether it may be submitted on a confidential basis. 

  

	 	i.	Monsanto understands that the New Put Option Shares have not been registered under the Securities Act and no public market now exists in the US for any of the securities issued by the Company and that the Company has
made no assurances that a public market will ever exist in the US for the Company’s securities. 

 Monsanto understands
that the New Put Option Shares, when issued, will be “restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to these laws, Monsanto must hold the New Put Option Shares indefinitely unless they
are registered with the Securities and Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification requirements is available. Monsanto acknowledges that Evogene has no obligation to register or
qualify the New Put Option Shares for resale in the U.S. Monsanto further acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and
manner of sale, the holding period for the New Put Option Shares, and on requirements relating to Evogene which are outside of Monsanto’s control, and which Evogene is under no obligation and may not be able to satisfy. 

 

	7.	Representations of Evogene 

  

	 	a.	It is a public company formed under the laws of the State of Israel, whose securities are listed for trade on the TASE. 

  

	 	b.	It has the full corporate power and authority to execute and deliver this Agreement and to consummate the transactions contemplated hereby. Evogene has duly and validly executed and delivered this Agreement, and
assuming compliance by Monsanto herewith, this Agreement when executed by Evogene will constitute valid, binding and enforceable obligations of Evogene in accordance with its terms. 

 

	 	c.	 The Company has timely filed with the Israel Securities Authority (the “ISA”) and the TASE all the required reports and notices in
accordance with the Securities Law and 

  
 -8- 

	 	
the Regulations (collectively, the “Reports”). The annual report for the year 2012 and the Reports filed by the Company since the publication thereof are incorporated herein by
reference, were true, accurate and complete as of the date filed with the TASE and/or the ISA, as applicable, contain all the information that is necessary for a reasonable investor considering purchasing securities of the Company at the time of
their publication and as of the date hereof, and no material information was omitted therefrom (except as set forth in the Share Purchase Agreement and the 2nd Amended and Restated Collaboration
Agreement), the absence of which could mislead a reasonable investor. 

  

	 	d.	Evogene has received no valid notice from the TASE of any intention to delist its securities from trading and/or transfer of Evogene’s securities to a watch list, and has no reason to believe that the issuance of
the New Put Option Shares would cause any of Evogene’s securities to be delisted from trading or transferred to a watch list. 

  

	 	e.	Except for the Premerger Confirmation, the TASE Approval and the issuance of the letters described in clause 2(b) which are required in the event Evogene exercises the New Put Option, no consents, approvals,
authorizations or permits are required in connection with the consummation by Evogene of the transactions contemplated by this Agreement. 

  

	 	f.	Based solely on the number of Evogene shares held by Monsanto on the Signing Date, the number of Evogene shares that Monsanto would acquire upon exercise of the New Put Option at the Minimum Exercise Price, and the
facts and circumstances known to Evogene on the Signing Date, and assuming that Monsanto acquires no additional shares of Evogene other than by virtue of exercise of the New Put Option and/or purchases in a US IPO that reduce the number of shares to
be issued pursuant to the New Put Option and no other change to the facts and circumstances known to Evogene on the Signing Date relating to Monsanto or to Evogene, Evogene would not deem Monsanto to be a “controlling shareholder” of
Evogene within the meaning of the Securities Law or the Israeli Companies Law – 1999 immediately after exercise of the New Put Option. 

  

	8.	Term and Termination 

 This Agreement shall become effective on and as of the Signing
Date when it has been executed and delivered by each of the parties hereto, and when the 2nd Amended and Restated Collaboration Agreement has been executed and delivered by the parties, and shall
terminate (without derogating from the effectiveness of Section 5 of this Agreement) upon the expiration of the New Put Option or, if the New Put Option is exercised in accordance with the terms hereof, upon the issuance of the New Put Option
Shares. 
  

	9.	Miscellaneous 

  

	 	a.	The parties will effect all the acts and sign all the documents that will be reasonably required in order to accomplish and fully effectuate the provisions of this Agreement and the intention of the parties that are
reflected by the contents thereof. 

  
 -9- 

	 	b.	This Agreement contains and expresses all the terms and conditions agreed between the parties with respect to the subject matter hereof. Any assurances, guarantees, written or verbal agreements, undertakings or
representations regarding the subject matter of this Agreement, including memoranda of understanding, that have been given or made by the parties between them, but prior to the making of this Agreement, and which have not been expressly stated in
this Agreement, will not add to nor derogate from the undertakings and rights prescribed in this Agreement or resulting therefrom, and the parties will not be bound thereby from the date of the signature of this Agreement onwards. 

 

	 	c.	No waiver, extension, concession or forbearance from exercising any right under this Agreement will be of any effect unless made by express document signed by the waiving party, and if made will only apply with respect
to the specific instance mentioned in the document and will not derogate from any other rights of any of the parties under this Agreement. This Agreement may be amended only by a written agreement executed by both parties. 

 

	 	d.	None of the parties may assign or convey any undertaking or right which it has under this Agreement without the prior consent of the other party; provided that Monsanto shall be permitted to designate a subsidiary of
Monsanto to be the direct purchaser of the New Put Option Shares, in which case Monsanto shall cause such subsidiary to observe and fulfill any and all obligations of Monsanto hereunder with respect to the purchase of the New Put Option Shares (and
if requested by Evogene, to provide to Evogene the representations provided to Evogene pursuant to Section 6 of this Agreement, mutatis mutandis). 

  

	 	e.	Notices under this Agreement will be conveyed in writing to the addresses of the parties appearing at the preamble of this Agreement and to the email addresses detailed hereunder. Any notice sent by either of the
parties to the other by registered mail will be deemed to have been received after four business days from the date of posting. Notice sent by fax or emailed will be deemed to have been received on the same business day on which it was sent (subject
to despatch confirmation being furnished). Notice given by personal service will be deemed to have been received on the date of service. 

Monsanto’s fax number and email address: (314)-694-2594, jennifer.l.woods@monsanto.com 

Evogene’s fax number and email address: +972-8-946-6724, haviv@evogene.com 

 

	 	f.	In case any provision of the Agreement shall be held invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. The
parties hereto shall be obliged to draw up an arrangement in accordance with the meaning and the object of the invalid provision. 

  
 -10- 

	 	g.	Other than as to matters governed by Israeli corporate or securities laws, which shall apply in such cases, this Agreement, including all Appendices hereto, shall be governed exclusively by, and construed solely in
accordance with, the laws of the State of New York, without regard to the conflict of laws provisions thereof. All disputes arising under this Agreement or in connection with the transactions hereunder shall be resolved exclusively in the competent
court in the district of Tel-Aviv, Israel. 

  

	 	h.	This Put Option Agreement may be executed in two counterparts and by facsimile, each of which will be deemed an original and which together will constitute one instrument. 

remainder of page left blank intentionally 

  
 -11- 

 In witness whereof the parties have set their hands on the date first above written:

  

					
	 /s/ Ofer Haviv
	 		 	 /s/ Thomas Ruff

	Evogene Ltd.	 		 	Monsanto Company
	Ofer Haviv	 		 	Thomas Ruff
	President & CEO	 		 	Director, Biotech Strategy

  
 -12-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]